N
GPCR icon

Natixis’s Structure Therapeutics GPCR Stock Holding History

Natixis’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135K Buy
+2,482
New +$110K ﹤0.01% 975

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Natixis's GPCR Position: Q2 2026 in Review

Natixis opened a new position in Structure Therapeutics (GPCR) in Q2 2026: 2,482 shares worth $135K. The stake represents ﹤0.01% of the portfolio and ranks #975 among its holdings.

192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Natixis held 2,482 shares of Structure Therapeutics worth $135K as of Q2 2026.
  • Structure Therapeutics was a new Natixis position in Q2 2026.
  • Structure Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #975 holding.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.